• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

BMC Infect Dis . Long-term immune responses in patients with confirmed novel coronavirus disease-2019: a 9-month prospective cohort study in Shangha

tetano

Editor, Senior Moderator
BMC Infect Dis


. 2022 Mar 10;22(1):240.
doi: 10.1186/s12879-022-07173-0.
Long-term immune responses in patients with confirmed novel coronavirus disease-2019: a 9-month prospective cohort study in Shanghai, China


Xiaohuan Gong[SUP] #[/SUP][SUP] 1 2 3 [/SUP], Peng Cui[SUP] #[/SUP][SUP] 2 [/SUP], Huanyu Wu[SUP] #[/SUP][SUP] 4 [/SUP], Hao Pan[SUP] #[/SUP][SUP] 2 [/SUP], Zheng Teng[SUP] #[/SUP][SUP] 5 [/SUP], Fang Yuan[SUP] 5 [/SUP], Shenghua Mao[SUP] 2 [/SUP], Dechuan Kong[SUP] 2 [/SUP], Ruobing Han[SUP] 2 [/SUP], Xue Zhao[SUP] 5 [/SUP], Yaxu Zheng[SUP] 2 [/SUP], Wenjia Xiao[SUP] 2 [/SUP], Yiyi Zhu[SUP] 2 [/SUP], Qiwen Fang[SUP] 2 [/SUP], Sheng Lin[SUP] 2 [/SUP], Bihong Jin[SUP] 2 [/SUP], Ruilin Chu[SUP] 2 [/SUP], Chenyan Jiang[SUP] 2 [/SUP], Xiao Yu[SUP] 2 [/SUP], Qi Qiu[SUP] 2 [/SUP], Yihan Lu[SUP] 1 3 [/SUP], Weibing Wang[SUP] #[/SUP][SUP] 6 7 [/SUP], Chen Fu[SUP] #[/SUP][SUP] 8 [/SUP], Xiaodong Sun[SUP] #[/SUP][SUP] 9 [/SUP]



Affiliations

Abstract

Background: The duration of antibodies against SARS-CoV-2 in Covid-19 patients remains uncertain. Longitudinal serological studies are needed to prevent disease and transmission of the virus.
Methods: In 2020, 414 blood samples were tested, obtained from 157 confirmed Covid-19 patients, in a prospective cohort study in Shanghai.
Results: The seropositive rate of IgM peaked at 40.5% (17/42) within 1 month after illness onset and then declined. The seropositive rate of IgG was 90.6% (58/64) after 2 months, remained above 85% from 2 to 9 months and was 90.9% (40/44) after 9 months. Generalized estimating equations models suggested that IgM (P < 0.001) but not IgG significantly decreased over time. Age ≥ 40 years (adjusted odds ratio [aOR] 4.531; 95% confidence interval [CI] 1.879-10.932), and cigarette smoking (aOR 0.344; 95% CI 0.124-0.951) were associated with IgG, and age ≥ 40 years (aOR 2.820; 95% CI 1.579-5.036) was associated with IgM. After seroconversion, over 90% and 75.1% of subjects were estimated to remain IgG-positive 220 and 254 days, respectively. Of 1420 self-reported symptoms questionnaires, only 5% reported symptoms 9 months after onset.
Conclusions: In patients with a history of natural infection, anti-SARS-CoV-2 IgG is long-lived, being present for at least 9 months after illness onset. The long duration of natural immunity can mitigate and eliminate Covid-19 and the ongoing pandemic.

Keywords: Antibodies; Cohort study; Covid-19; Immunity; SARS-CoV-2.
 
Back
Top Bottom